Terence Rhodes, MD
Hematology & Oncology · Cedar City, UTNPI 1124236310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,080 of the $146,654 with a category attached, or 83.9%. E.r. Squibb & Sons, L.L.C. accounts for 97.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $78,408 and has fallen 100.0% since, to $26 in 2024. Among hematology & oncology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $1173.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$143K
- AstraZeneca$2K
- Bristol Myers Squibb$910
- Amgen$627
- Genentech, Inc.$48
- Merck$47
- plus $75 from 4 others
Across 49 payments — averaging $3733.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$132K
- Bayer$31K
- E.r. Squibb & Sons, L.L.C.$20K
- Novartis$586
What the payments were for
- Consulting fees$10,4157%
- Speaking & faculty fees$123,08084%
- Travel & lodging$11,1898%
- Food & beverage$1,8851%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 103 | $143,130 |
| AstraZeneca | 4 | $1,818 |
| Bristol Myers Squibb | 3 | $910 |
| Amgen | 7 | $627 |
| Genentech, Inc. | 1 | $48 |
| Merck | 3 | $47 |
| Johnson & Johnson | 1 | $33 |
| Bayer | 1 | $17 |
| Novartis | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$146,654 in reported general payments places this provider in the 90th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 23 | $577,460 |
| Abiraterone Acetate | 27 | $4,997 |
| Betamethasone Dipropionate | 11 | $801 |
| Hydrocortisone | 16 | $368 |
| Prednisone | 56 | $304 |
| Dexamethasone | 12 | $268 |
| Potassium Chloride | 25 | $230 |
| Prochlorperazine Maleate | 14 | $227 |
| Levothyroxine Sodium | 22 | $182 |
| Ondansetron Hcl | 18 | $179 |
| Furosemide | 19 | $76 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cedar City
- Ryan WilcoxCedar City$9K
- Bryce PerkinsCedar City$548
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.